-
August 16, 2023 Lupin Launches Tiotropium Dry Powder Inhaler for the Treatment of COPD in the United States
-
August 16, 2023 Lupin Launches Jeet, a Patient Support Program to Raise Awareness of Cardiovascular Disease Among Patients
-
August 16, 2023 Lupin Receives Approval from U.S. FDA for Metoprolol Succinate Extended-Release Tablets USP
-
August 16, 2023 Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%
-
August 14, 2023 Lupin Receives Approval from U.S. FDA for Doxycycline Hyclate Delayed-Release Tablets USP
-
August 14, 2023 Lupin’s Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
-
August 8, 2023 Lupin Receives Approval from U.S. FDA for Fluocinolone Acetonide Body Oil
-
August 7, 2023 Lupin Digital Health Launches first-of-its-kind Digital Heart Failure Clinic in India
-
August 3, 2023 Lupin Q1 FY2024 Results
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications